(International Print/Online Journal)

SJIF IMPACT FACTOR: 5.565
PUBMED-National Library of Medicine ID-101739732

ISSN (Print): 2209-2870
ISSN (Online): 2209-2862

International Journal of Medical Science and Current Research (IJMSCR)
Available online at: www.ijmscr.com
Volume 5, Issue 2, Page No: 1163-1170
March-April 2022

IJMSCR

Effectiveness of the mRNA COVID-19 Vaccine in Pregnant Women

Napasawan Yeepu
Rayongwittayakom School,
Takin Maharat Rd, Mueang Rayong 21000

***Corresponding Author:**
Napasawan Yeepu
Rayongwittayakom School, Takin Maharat Rd, Mueang Rayong 21000

Type of Publication: Original Research Paper
Conflicts of Interest: Nil

Abstract

Due to the large epidemic situation of communicable diseases such as COVID-19, vaccination is required. Research has concluded that vaccination against COVID-19 is the best solution because it will help build the body's immunity, strengthen the immune system, and make the epidemic has subsided. Life will return to normal once the epidemic is under control. Vaccination is therefore vital for everyone, including pregnant women, for whom we want to investigate the efficacy of the mRNA COVID-19 vaccine because they are at risk. This article compiles data from studies in order to summarise efficacy and safety of the mRNA COVID-19 vaccination in pregnant women.

Keywords: COVID-19 vaccines; Pregnant Women; mRNA vaccines, mRNA-1273; BNT162b2

Introduction

There are several steps involved in bringing the vaccine to the public and must be approved by the US Food and Drug Administration (FDA) (1). Several government and non-governmental organizations have worked together to make the COVID-19 vaccine public after approval for emergency use for messenger RNA (mRNA) vaccines BNT162b2 (Pfizer–BioNTech) and mRNA-1273 (Moderna), in the at-risk population for the coronavirus disease 2019 (Covid-19) among them are pregnant women, but they are not exempt from preliminary vaccination trial (2, 3). Pregnant women and doctors must compare the risks of contracting Covid-19 with the unknown safety risks of vaccination in the decision to get vaccinated (4). From the research, it was found that pregnant women are at a greater risk than non-pregnant women for serious COVID-19 disease (5). This results in the need to be admitted to the ICU and to be closely monitored as pregnant women may be at increased risk of complications in pregnancy, including preterm birth cesarean section and preeclampsia associated with COVID-19 infection (6). During pregnancy, doctors rely on development and fertility (7). Animal genetic information from Modena shows no safety concerns and there is not a biological reason to believe that mRNA technology is harmful in pregnancy, it is advised to consider the available evidence and make personal decisions about vaccination in the absence of human safety data (8).

mRNA Covid-19 Vaccines in Pregnant Women

BNT162b2 (Pfizer–BioNTech) and mRNA-1273 (Pfizer–BioNTech) The Faculty of Medicine's Emergency Vaccine (EUA) messenger RNA (mRNA) vaccines are the first coronavirus 2019 (Covid-19) vaccines available in the United States (Moderna) (3). The Food and Drug Administration (FDA) has approved a two-dose vaccine that provides Pfizer–BioNTech 3 weeks apart and Moderna 1 month apart (9). This information was recommended by the Immunization Advisory Committee (ACIP) (10, 11). Pregnant women who are receiving immunotherapy are barred from participating in pre-approval clinical trials. Furthermore, there seems to

be little sentient data on its protection during pregnancy once permitted (12). Both mortality and morbidity are at risk (13). Others who are not infertile experience worse symptoms (14). Furthermore, pregnant women infections caused with COVID-19 may be at a higher risk of unfavorable pregnancy outcomes (15). The Centers for Disease Control and Prevention (CDC), in collaboration with the American Clinical practice Guidelines and the American Academy of Pediatrics, has issued guidelines stating that Covid-19 vaccine should also not be withheld from pregnant women (8, 16).

To define the safety of these new Covid-19 vaccines, which add mRNA, lipid nanoparticles, and cutting-edge production procedures, post-authorization surveillance in pregnant women is required (16, 17). Furthermore, determining their safety profiles is crucial in order to make informed recommendations on maternal Covid-19 vaccination (18). We provide preliminary findings from three vaccine safety monitoring systems in the United States: the "v-safe post vaccination health checker" safety system, the v-safe pregnancy registry, and the Vaccine Adverse Event Reporting System (VAERS) (19). The V-safe pregnancy registry, a new smartphone surveillance system from the Centers for Disease Control and Prevention that gives information on the safety of these vaccines to pregnant women, begins with the V-safe pregnancy registry (20). During the 12 months following immunization, all COVID-19 vaccine recipients will get a message asking them to assess their overall health and pregnancy status (16). Individuals who pregnants can join the v-safe pregnancy register, which will contact them by phone to ask more detailed questions (21). The safety data for v-safe participants 16 to 54 years old who were identified as pregnant and enrolled in the first two groups showed that 54% received the Pfizer-BioNTech vaccination and 54% received the Moderna vaccine. 86.5% of v-safe participants had a known pregnancy at the time of vaccination, and 13.5% had a positive pregnancy test afterward (19, 22). The vaccine was given to 28.6% of v-safe pregnancy registry participants in the first trimester, 43.3% in the second trimester, and 25.7% in the third trimester (15).

A spontaneous abortion occurs 12.6% of the time in completed pregnancies, while stillbirth occurs 0.1% of the time. Preterm birth (9.4%), small size for gestational age (3.2%), and congenital abnormalities (2.2%) were all found in live-born newborns, however there were no neonatal deaths (23, 24). Pregnant women are confident about vaccinations based on this information. Furthermore, the rates of local and systemic reactions after vaccination were found to be comparable to those found in the general population of non-pregnant women (22). This means that pregnancy has no influence on the reaction. . The most common side effect is injection site pain, which is accompanied by fatigue, headache, and muscle pain (19). After the second dose, such symptoms have been widely reported. Fever was reported in fewer people after the first dose, and in about one-third of those who received the second dose (19). Reportedly, There are quite a few pregnancies on scheduled pregnancy and normal pulse after vaccination (25). Team acknowledged restrictions in their capacity to draw interpretations about abnormalities, but birth and other possible outcomes of newborns (24). Despite these limitations, this report provides key information that has never been seen before (24).

Currently, the epidemic is in progress and expectant women are found in higher danger of severe illness if altered with COVID-19 (26). Inoculation is an important preventive strategy, but the lack of security info about vaccination during gestation has forced thousands of pregnant women to be cautious in their resolution about vaccination (26). It underscores the significance if registration of pregnant women in case, including ongoing vaccine trials (7). An experiment is currently underway to learn the results of the BNT162b2 vaccine in pregnant women and their newborn ClinicalTrials.gov number, NCT04754594) (7).

Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy

Hundreds of millions of people globally have indeed been infected with the SARS-CoV-2 virus, and millions had also died as a result of COVID-19 and its complications (8). Vaccines are the most effective way to halt the propagation of the epidemic (9). Despite the greater risk of acquiring the severe COVID-19 virus as a result of an unwanted pregnancy Pregnant women, on the other hand, are still not excluded from phase III clinical investigation promoting the safety and efficacy of the COVID-19

Volume 5, Issue 2; March-April 2022; Page No 1163-1170

mRNA vaccine (27). Latest studies are concentrating on gestational vaccination and surrogate effectiveness (that is, immunogenicity) (28). Vaccination guidance for pregnant women have indeed been incongruent due to a lack of evidence regarding the arcuate'safety and effectiveness in this population (28). There have been no obvious safety signals associated with vaccines in pregnant women, according to initial reports9. However, data on vaccine effectiveness in pregnant women remain scarce (29). As the global vaccination rate increases, there is an opportunity to evaluate the mRNA COVID-19 vaccines' real-world effectiveness and safety using observational data (30). It is well-known that pregnancy has an impact on the immune system (26). There's really evidence that levels of CD4+ and CD8+ lymphocytes, as well as some inflammatory cytokines, decrease during pregnancy. mRNA vaccines, which are new and were not extensively tested throughout pregnant women, may well have various impacts on pregnant women than on the overall population, emphasizing the importance of assessing vaccine efficacy in this subgroup (31). A previous study discovered that pregnant women's trust in the vaccine's efficacy highly linked with their eagerness to end up receiving the COVID-19 vaccine (32).

Pregnant women get the same level of protection from the BNT162b2 mRNA COVID-19 vaccine as the general public did during the same time period: 96% effectiveness against substantiated infection and 97% effectiveness against symptomatic infection (28). Seven to fifty-six days just after second dose of vaccine (28). These finding indicate the vaccine's primary efficacy against by the original SARS-CoV-2 susceptible strain as well as the B.1.1.7 (Alpha) variation, which have been the predominant strains making the rounds in Israel during the period of study (28, 29). Although the vaccine's estimated efficiency against COVID-19-related hospital treatment was high, accurate assessment was impossible due to a lack of cases (29).

Because pregnant women were excluded from the initial phase iii trials, information on the effectiveness of the fresh mRNA COVID-19 flu shots in this population are rare and expensive in the medical journals (8). In one study, the vaccines were found to be immunogenic in pregnant women besides eliciting humoral and cellular immune reactions against SARS-CoV-2 (33).

Using data from healthcare organizations with the same variety of genetic variants, the efficacy of the BNT162b2 mRNA COVID-19 vaccine in the general public was evaluated (27). Vaccine efficacy after the 14th dose was approximately 92 percent (88–95 percent) for documented infections and 94 percent (87–98 percent) for symptomatic infections (34). Ninety five per cent of those surveyed were confident that an up to date assessment of same data would be conducted. For documented infections, those who were approximately 93 % (91–94 %) and then for simply a symptom infections diseases, they were approximately 96 % (94–97%) (34). According to our findings, the vaccine's efficiency in pregnant women has been significant compared to it in the general population (9). These results support the notion that pregnant women have a higher prevalence of comorbidities than the general population (35). The findings indicate that prospective vaccine efficacy in the general population could be used to forecast the efficacy of the same variable in pregnant women (35). This is especially true for vaccines based on mRNA (35).

Vaccination may also be beneficial to pregnant women in order to protect their unborn children (36). A recent study found binding and neutralizing immunoglobulin inside the cord blood and breast feeding of children born to mothers who already had mRNA vaccines (33). Another study found that getting vaccinated breastfeeding women increased the amount of anti-SARS-CoV-2 antibodies specific in their breastfeeding (37). At the moment, the extent and length of time of this prospective protection are unknown. This research has a high likelihood of producing misunderstanding, especially if prenatal care is not a concern (37). However, in the early post-first vaccination period, there was still a considerable consistency in recorded and symptomatic infection prevalence between the two study groups, showing that even if there is a slight residual disturbance, it will be detected (38). Because more serious incidents are uncommon, we were unable to provide estimates of a vaccine's effectiveness for these occurrences in the second phase of our research (39, 40). A considerable fraction of the research's eligible population was eliminated due to the strict matching process required to allow exchange between study groups during the third phase (41). As a result, the number of women in the final study sample who had

Volume 5, Issue 2; March-April 2022; Page No 1163-1170

specific chronic conditions reduced marginally (42, 43). As previously observed, vaccine efficacy among women with chronic illnesses may be slightly lower than the average vaccine efficacy tested in this study (43). The findings suggest that the BNT162b2 mRNA COVID-19 vaccination is extremely successful in pregnant women against the variations that were circulating in Israel at the time of the study, with vaccine efficacy comparable to that estimated in the general population (39). More research is needed to completely understand the dynamics of vaccine effectiveness during pregnancy, the link between immunization timing and infant protection after delivery, and pregnancy and non-pregnancy outcomes (41, 44).

COVID-19 mRNA vaccines offer protection against Omicron variant in pregnancy

The antibody and receptor binding crystallization (Fc) pattern of the worrisome severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strains (VOCs), which included omicron (mRNA) in pregnant women, was investigated by researchers (45). In 2019, SARS-CoV-2 infection has been related to a higher chance of developing severe coronavirus disease (COVID-19) (33, 45). In the first vaccine study, however, pregnancy was employed as a barrier. Causing the vaccine to be delayed in this population (46, 47). A study of pregnant women discovered a high antibody count after immunization mRNA shortly after the COVID-19 vaccine was licensed for emergency use (EUA) (1, 10). The COVID-19 outbreak was caused by the existence of an Omicron modified version of vaccine-induced opsonophagocytosis and cytotoxicity against severe SARS-CoV-2 infection in animals (48). The COVID-19 mRNA vaccine, on the other hand, has been demonstrated to protect pregnant women against the developing SARS-CoV-2 Omicron and other VOCs (49). The ability of the SARS-CoV-2 Omicron variation and other VOCs to bind to the Fc receptor was examined in pregnant women who had received two doses of the Pfizer (BNT62b2) or Moderna (mRNA-1273) vaccines, which selectively target the antibody's receptor-binding domain (RBD) or spike (S) (49, 50).

Single pregnant women at least 18 years old and who have given their informed consent to participate in the study were eligible to participate (51). After two to four weeks of vaccination with two doses of Moderna or Pfizer, ten samples were collected from each of the two vaccination groups (51). RBD antigens for the SARS-CoV-2 wildtype (WT), alpha, beta, delta VOCs, and Omicron were provided by Sino-Biologicals and Moderna Incorporated (52). Besides that, the S protein of all SARS-CoV-2 VOCs was stabilized using HEK293 cells (50). The antigen-specific antibody subclass, isotypes, and Fc receptor binding of SARS-CoV-2 VOCs were determined using the Luminex multiplexing assay (49). The ability of Moderna and Pfizer vaccine-induced antibodies to bind immunoglobulin G (IgG), IgA, and IgM isotypes was found to be largely preserved across the Delta, WT, Alpha, and Beta VOC' RBDs (50). In comparison, the Pfizer and Moderna vaccines reduced IgG, IgA, and IgM binding to the Omicron RBD by 16 to 24 fold and 10 to 23 fold, respectively (50). Pfizer's binding to Omicron RBD decreased significantly in comparison to the significant decrease in binding to Omicron RBD (50, 53). In comparison to WT SARS-CoV-2, Moderna vaccination responses to Omicron were lower across all three isotypes. Moderna vaccination users showed a higher amount of anti-Spike IgG and IgM feedback and better IgA responses than Pfizer vaccine recipients as compared to total VOCs (53). By reason of the collective, extra consistent, or over antibody titrations induced by Moderna vaccinations brings the compelling decrease in Omicron-specific isotype confining in Moderna-vaccinated childbearing women, Omicron recognition levels were proportionate betwixt the Moderna and Pfizer mRNA vaccines (54). Antibodies generated by the Moderna and Pfizer vaccinations were capable of binding to entire Fc-receptors in contrast to WT, Alpha, Beta, and Delta VOCs (38, 55). Vaccine-induced Omicron RBD-specific antibodies, on the other hand, lost all Fc-receptor binding (50). Regardless, S-specific antibodies exist (56, 57).

Conclusion

The mRNA vaccines offer significant protection against documented SARS-CoV-2 infection, which supports the vaccination of pregnant women. The CDC issued an urgent health advisory urging pregnant women, those who have recently given birth (including those who are lactating), those who are currently trying to conceive, or those who may become pregnant in the future, to increase COVID-19

Volume 5, Issue 2; March-April 2022; Page No 1163-1170

vaccination in order to avoid serious illness, death, and adverse pregnancy outcomes. The study sheds light on the persistence of antibodies induced by extra-neutralising mRNA vaccines and confers protection against the Omicron variant. The current findings can serve as a guide for future vaccination and booster vaccination campaigns targeting pregnant women. Further research is needed to determine whether Fc-receptor recruitment alone is sufficient to provide robust protection against Omicron and the effects of booster vaccination on the recruiting qualities of Fc-receptors and the duration of the Fc functions.

References

1. Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al. The advisory committee on immunization practices' interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine—United States, December 2020. Morbidity and mortality weekly report. 2020;69(50):1922.
2. Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, Meece J, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers—eight US locations, December 2020–March 2021. Morbidity and Mortality Weekly Report. 2021;70(13):495.
3. Pilishvili T, Gierke R, Fleming-Dutra KE, Farrar JL, Mohr NM, Talan DA, et al. Effectiveness of mRNA Covid-19 vaccine among US health care personnel. New England Journal of Medicine. 2021;385(25):e90.
4. Hernández AF, Calina D, Poulas K, Docea AO, Tsatsakis AM. Safety of COVID-19 vaccines administered in the EU: Should we be concerned? Toxicol Rep. 2021;8:871-9.
5. Atyeo C, DeRiso EA, Davis C, Bordt EA, DeGuzman RM, Shook LL, et al. COVID-19 mRNA vaccines drive differential Fc-functional profiles in pregnant, lactating, and non-pregnant women. bioRxiv. 2021.
6. Bookstein Peretz S, Regev N, Novick L, Nachshol M, Goffer E, Ben-David A, et al. Short-term outcome of pregnant women vaccinated with BNT162b2 mRNA COVID-19 vaccine. Ultrasound in Obstetrics & Gynecology. 2021;58(3):450-6.
7. Bowman CJ, Bouressam M, Campion SN, Cappon GD, Catlin NR, Cutler MW, et al. Lack of effects on female fertility and prenatal and postnatal offspring development in rats with BNT162b2, a mRNA-based COVID-19 vaccine. Reproductive Toxicology. 2021;103:28-35.
8. Rasmussen SA, Kelley CF, Horton JP, Jamieson DJ. Coronavirus disease 2019 (COVID-19) vaccines and pregnancy: what obstetricians need to know. Obstetrics and gynecology. 2021;137(3):408.
9. Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. The Lancet. 2021;397(10287):1819-29.
10. MacNeil JR, Su JR, Broder KR, Guh AY, Gargano JW, Wallace M, et al. Updated recommendations from the Advisory Committee on Immunization Practices for use of the Janssen (Johnson & Johnson) COVID-19 vaccine after reports of thrombosis with thrombocytopenia syndrome among vaccine recipients—United States, April 2021. Morbidity and Mortality Weekly Report. 2021;70(17):651.
11. Oliver SE. The advisory committee on immunization practices' interim recommendation for use of moderna COVID-19 vaccine—United States, December 2020. MMWR Morbidity and mortality weekly report. 2021;69.
12. Low JM, Gu Y, Ng MSF, Zubair A, Ng YPM, Bhuvaneshwari D, et al. BNT162b2 vaccination induces SARS-CoV-2 specific antibody secretion into human milk with minimal transfer of vaccine mRNA. medRxiv. 2021.
13. Male V. SARS-CoV-2 infection and COVID-19 vaccination in pregnancy. Nature Reviews Immunology. 2022:1-6.
14. Stock SJ, Carruthers J, Calvert C, Denny C, Donaghy J, Goulding A, et al. SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland. Nature medicine. 2022:1-9.

Volume 5, Issue 2; March-April 2022; Page No 1163-1170

15. Simionescu AA, Bejan GC, Adam A-M, Alexandra Stanescu AM. Immunity and COVID-19 vaccines in pregnancy–precautions and risks. Romanian Journal of Medical Practice. 2021;16(2).
16. Moro PL, McNeil MM. Successes of the CDC monitoring systems in evaluating post-authorization safety of COVID-19 vaccines. Taylor & Francis; 2022.
17. Wu Q, Dudley MZ, Chen X, Bai X, Dong K, Zhuang T, et al. Evaluation of the safety profile of COVID-19 vaccines: a rapid review. BMC medicine. 2021;19(1):1-16.
18. Laczkó D, Hogan MJ, Toulmin SA, Hicks P, Lederer K, Gaudette BT, et al. A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice. Immunity. 2020;53(4):724-32.
19. Rosenblum HG, Gee J, Liu R, Marquez PL, Zhang B, Strid P, et al. Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe. The Lancet Infectious Diseases. 2022.
20. Zauche LH, Wallace B, Smoots AN, Olson CK, Oduyebo T, Kim SY, et al. Receipt of mRNA Covid-19 vaccines and risk of spontaneous abortion. New England Journal of Medicine. 2021;385(16):1533-5.
21. Soysal A, Bilazer C, Gönüllü E, Barın E, Çivilibal M. Cord blood antibody following maternal SARS-CoV-2 inactive vaccine (CoronaVac) administration during the pregnancy. Human Vaccines & Immunotherapeutics. 2021;17(10):3484-6.
22. Zauche LH, Wallace B, Smoots AN, Olson CK, Oduyebo T, Kim SY, et al. Receipt of mRNA COVID-19 vaccines preconception and during pregnancy and risk of self-reported spontaneous abortions, CDC v-safe COVID-19 Vaccine Pregnancy Registry 2020-21. 2021.
23. Bartoszek K, Okrój M. Controversies around the statistical presentation of data on mRNA-COVID 19 vaccine safety in pregnant women. Journal of Reproductive Immunology. 2022:103503.
24. Shimabukuro TT, Kim SY, Myers TR, Moro PL, Oduyebo T, Panagiotakopoulos L, et al. Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons. New England Journal of Medicine. 2021.
25. Halasa NB, Olson SM, Staat MA, Newhams MM, Price AM, Boom JA, et al. Effectiveness of Maternal Vaccination with mRNA COVID-19 Vaccine During Pregnancy Against COVID-19–Associated Hospitalization in Infants Aged< 6 Months—17 States, July 2021–January 2022. Morbidity and Mortality Weekly Report. 2022;71(7):264.
26. Atyeo C, DeRiso EA, Davis C, Bordt EA, De Guzman RM, Shook LL, et al. COVID-19 mRNA vaccines drive differential antibody Fc-functional profiles in pregnant, lactating, and nonpregnant women. Science Translational Medicine. 2021;13(617):eabi8631.
27. Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, et al. Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. New England Journal of Medicine. 2021.
28. Dagan N, Barda N, Biron-Shental T, Makov-Assif M, Key C, Kohane IS, et al. Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy. Nature medicine. 2021;27(10):1693-5.
29. Luxi N, Giovanazzi A, Capuano A, Crisafulli S, Cutroneo PM, Fantini MP, et al. COVID-19 vaccination in pregnancy, paediatrics, immunocompromised patients, and persons with history of allergy or prior SARS-CoV-2 infection: overview of current recommendations and pre-and post-marketing evidence for vaccine efficacy and safety. Drug safety. 2021;44(12):1247-69.
30. Chodick G, Tene L, Rotem RS, Patalon T, Gazit S, Ben-Tov A, et al. The effectiveness of the TWO-DOSE BNT162b2 vaccine: analysis of real-world data. Clinical Infectious Diseases. 2022;74(3):472-8.
31. Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020;586(7830):594-9.
32. Balicer R, Dagan N, Barda N, Biron-Shental T, Makov-Assif M, Key C, et al. Effectiveness of

Volume 5, Issue 2; March-April 2022; Page No 1163-1170

the BNT162b2 mRNA COVID-19 Vaccine in Pregnancy. 2021.
33. Ai-ris YC, McMahan K, Yu J, Tostanoski LH, Aguayo R, Ansel J, et al. Immunogenicity of COVID-19 mRNA vaccines in pregnant and lactating women. Jama. 2021;325(23):2370-80.
34. Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet. 2021;397(10285):1646-57.
35. Savasi VM, Parisi F, Patanè L, Ferrazzi E, Frigerio L, Pellegrino A, et al. Clinical findings and disease severity in hospitalized pregnant women with coronavirus disease 2019 (COVID-19). Obstetrics & Gynecology. 2020;136(2):252-8.
36. Blumberg D, Sridhar A, Lakshminrusimha S, Higgins RD, Saade G. COVID-19 vaccine considerations during pregnancy and lactation. American journal of perinatology. 2021;38(06):523-8.
37. Davanzo R, Agosti M, Cetin I, Chiantera A, Corsello G, Ramenghi LA, et al. Breastfeeding and COVID-19 vaccination: position statement of the Italian scientific societies. Italian Journal of Pediatrics. 2021;47(1):1-4.
38. Dzinamarira T, Tungwarara N, Chitungo I, Chimene M, Iradukunda PG, Mashora M, et al. Unpacking the Implications of SARS-CoV-2 Breakthrough Infections on COVID-19 Vaccination Programs. Vaccines. 2022;10(2):252.
39. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. New England Journal of Medicine. 2021.
40. Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, et al. Waning 2-Dose and 3-Dose effectiveness of mRNA vaccines against COVID-19–associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance—VISION Network, 10 States, August 2021–January 2022. Morbidity and Mortality Weekly Report. 2022;71(7):255.
41. Barda N, Dagan N, Cohen C, Hernán MA, Lipsitch M, Kohane IS, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. The Lancet. 2021;398(10316):2093-100.
42. Charepe N, Gonçalves J, Juliano AM, Lopes DG, Canhão H, Soares H. COVID-19 mRNA vaccine and antibody response in lactating women: a prospective cohort study. BMC pregnancy and childbirth. 2021;21(1):1-9.
43. Goldschmidt K. COVID-19 vaccines for children: The essential role of the pediatric nurse. Journal of pediatric nursing. 2021;57:96.
44. Beharier O, Mayo RP, Raz T, Sacks KN, Schreiber L, Suissa-Cohen Y, et al. Efficient maternal to neonatal transfer of antibodies against SARS-CoV-2 and BNT162b2 mRNA COVID-19 vaccine. The Journal of clinical investigation. 2021;131(13).
45. Zagorski K, Pandey K, Rajaiah R, Olwenyi O, Bade A, Acharya A, et al. Peptide Nanoarray Scaffold Vaccine for SARS-COV-2 and Its Variants of Concerns. 2022.
46. Golob JL, Lugogo N, Lauring AS, Lok AS. SARS-CoV-2 vaccines: a triumph of science and collaboration. JCI Insight. 2021;6(9).
47. Mirzaei R, Mohammadzadeh R, Mahdavi F, Badrzadeh F, Kazemi S, Ebrahimi M, et al. Overview of the current promising approaches for the development of an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. International immunopharmacology. 2020;88:106928.
48. Britton A, Slifka KMJ, Edens C, Nanduri SA, Bart SM, Shang N, et al. Effectiveness of the Pfizer-BioNTech COVID-19 vaccine among residents of two skilled nursing facilities experiencing COVID-19 outbreaks—Connecticut, December 2020–February 2021. Morbidity and Mortality Weekly Report. 2021;70(11):396.
49. Kaplonek P, Cizmeci D, Fischinger S, Collier A-r, Suscovich T, Linde C, et al. Subtle immunological differences in mRNA-1273 and BNT162b2 COVID-19 vaccine induced Fc-functional profiles. bioRxiv. 2021.
50. Bartsch Y, Atyeo C, Kang J, Gray KJ, Edlow AG, Alter G. Preserved recognition of Omicron

Volume 5, Issue 2; March-April 2022; Page No 1163-1170

Spike following COVID-19 mRNA vaccination in pregnancy. medRxiv. 2022.
51. Falsaperla R, Leone G, Familiari M, Ruggieri M. COVID-19 vaccination in pregnant and lactating women: a systematic review. Expert Review of Vaccines. 2021;20(12):1619-28.
52. Kumari D, Prasad BD, Dwivedi P, Sahni S. COVID-19 Vaccines: A possible solution to ongoing pandemic. 2021.
53. Khandia R, Singhal S, Alqahtani T, Kamal MA, Nahed A, Nainu F, et al. Emergence of SARS-CoV-2 Omicron (B. 1.1. 529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic. Environmental Research. 2022:112816.
54. Sievers BL, Chakraborty S, Xue Y, Gelbart T, Gonzalez JC, Cassidy AG, et al. Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses. Science translational medicine. 2022:eabn7842.
55. Mohapatra RK, Tiwari R, Sarangi AK, Islam MR, Chakraborty C, Dhama K. Omicron (B. 1.1. 529) variant of SARS-CoV-2: Concerns, challenges, and recent updates. Journal of medical virology. 2022.
56. Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, et al. Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant. New England Journal of Medicine. 2022.
57. Sievers BL, Chakraborty S, Xue Y, Gelbart T, Gonzalez JC, Cassidy AG, et al. Magnitude and breadth of neutralizing antibody responses elicited by SARS-CoV-2 infection or vaccination. medRxiv. 2022:2021-12.

Volume 5, Issue 2; March-April 2022; Page No 1163-1170